Statute Details
- Title: Medicines (Cessation of Application of Act to Oral Dental Gums) Order 2016
- Act Code: MA1975-S542-2016
- Legislative Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), section 77
- Legislation Number: S 542/2016
- Date Made: 31 October 2016
- Key Effective Date: 1 November 2016 (cessation and transitional deeming)
- Key Definitions: “oral dental gum”, “Oral Dental Gums Regulations”, “product licence”, “registrant”
- Key Provisions: Section 3 (cessation of application of the Medicines Act to oral dental gums); Section 4 (saving and transitional provisions)
What Is This Legislation About?
The Medicines (Cessation of Application of Act to Oral Dental Gums) Order 2016 (“the Order”) is a regulatory “switch-over” instrument. In plain terms, it stops the Medicines Act regime from applying to a specific category of products—oral dental gums—and moves them into a different regulatory framework under the Health Products Act (Cap. 122D).
Oral dental gums are chewing gums (or similar substances) intended to be chewed for dental health or oral hygiene. The Order defines this category carefully and then provides that, from 1 November 2016, the provisions of the Medicines Act cease to apply to such products. This is not a repeal of the Medicines Act; rather, it is a targeted cessation for a defined product class.
Because regulatory regimes often involve licences, registrations, and compliance duties, the Order also contains saving and transitional provisions. These provisions ensure that existing licences and authorisations granted under the Medicines Act do not simply expire or become legally meaningless overnight. Instead, they are “deemed” to be licences or statuses under the Health Products Act and the relevant subsidiary regulations.
What Are the Key Provisions?
1. Citation and scope (Sections 1 and 2)
Section 1 provides the short title of the Order. Section 2 sets out definitions that determine what products are captured and how the Order should be read alongside other legislation.
The definition of “oral dental gum” is central. It includes any chewing gum (or like substance) prepared from a gum base of vegetable or synthetic origin and intended to be chewed to promote dental health or oral hygiene. Importantly, the definition excludes gums manufactured or imported into Singapore solely for research and development by a person registered under the Control of Manufacture Act (Cap. 57) in respect of the manufacture of chewing gum. This carve-out reflects a common regulatory approach: products for R&D may be treated differently from products marketed for consumer use.
The Order also defines “Oral Dental Gums Regulations” as the Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016). This signals that the new regime is not only the Health Products Act but also specific regulations tailored to oral dental gums.
2. Cessation of application of the Medicines Act (Section 3)
Section 3 is the operative “switch” provision. It states that the provisions of the Medicines Act cease to apply to any oral dental gum as from 1 November 2016.
For practitioners, the practical consequence is that compliance obligations, licensing/registration pathways, and enforcement mechanisms that previously applied under the Medicines Act no longer govern oral dental gums after the effective date. Instead, the Health Products Act and the Oral Dental Gums Regulations become the relevant legal framework.
3. Transitional deeming for existing product licences (Section 4(1) and (2))
Section 4 is designed to prevent regulatory disruption. Under sub-section (1), every oral dental gum for which a product licence is valid immediately before 1 November 2016 is deemed, on or after that date and for as long as the product licence remains valid, to be registered as an oral dental gum under the Health Products Act.
Sub-section (2) then addresses the status of the licence holder. The holder of such a product licence is deemed to be a “registrant” under the Health Products Act and is subject to the duties of a registrant from 1 November 2016 onward (again, for so long as the product licence remains valid).
This is a significant legal bridge: it converts a Medicines Act “product licence” position into a Health Products Act “registration/registrant” position without requiring immediate re-registration, while also ensuring that the holder is subject to the new compliance duties.
4. Transitional treatment of import, manufacturer, and wholesale dealer licences (Sections 4(3) to (6))
The Order also deals with the licensing chain beyond the product itself. Under sub-section (3), every import licence for the import of an oral dental gum that is valid immediately before 1 November 2016 is treated, from that date and for as long as it remains valid, as if it were an importer’s licence under section 13 of the Health Products Act.
Similarly, sub-section (4) provides that every manufacturer’s licence granted under section 6(2) of the Medicines Act (for oral dental gums) and valid immediately before 1 November 2016 is treated as if it were a manufacturer’s licence under section 12 of the Health Products Act.
Sub-section (5) provides the same approach for wholesale dealer’s licences, treating them as if they were wholesaler’s licences under section 14 of the Health Products Act.
Finally, sub-section (6) clarifies that the holders of these licences are deemed to be the corresponding licence holders under the Health Products Act and are subject to the duties of those holders from 1 November 2016 for so long as the licences remain valid.
For legal and compliance teams, this means that operational responsibilities—such as record-keeping, quality-related obligations, and regulatory cooperation—shift to the Health Products Act framework immediately upon the effective date, even though the underlying licences were originally issued under the Medicines Act.
How Is This Legislation Structured?
The Order is concise and structured around four provisions:
Section 1 sets out the citation. Section 2 provides definitions, including the product category (“oral dental gum”) and cross-references to the Oral Dental Gums Regulations and the Health Products Act concepts of “registrant” and licensing.
Section 3 contains the core legal effect: cessation of the Medicines Act’s application to oral dental gums from 1 November 2016.
Section 4 contains the saving and transitional provisions. It provides a series of deeming rules that (i) convert product licences into registrations, and (ii) convert import/manufacturing/wholesale licences into the corresponding licences under the Health Products Act, while also imposing the relevant duties on the deemed registrants and licence holders.
Who Does This Legislation Apply To?
The Order applies to oral dental gums as defined in section 2. It affects the regulatory treatment of these products by changing which Act governs them. As a result, it also affects the persons who hold licences or registrations relating to such products.
Practically, the Order impacts:
- Product licence holders (deemed to become registrants under the Health Products Act);
- Importers (deemed to hold importer’s licences under the Health Products Act);
- Manufacturers (deemed to hold manufacturer’s licences under the Health Products Act); and
- Wholesalers (deemed to hold wholesaler’s licences under the Health Products Act).
The transitional provisions apply to those licences and product authorisations that were valid immediately before 1 November 2016. After that date, the new regime governs, and holders are subject to the duties under the Health Products Act and the Oral Dental Gums Regulations.
Why Is This Legislation Important?
This Order is important because it demonstrates how Singapore manages regulatory transitions without creating legal gaps. When a product category moves from one statutory regime to another, there is a risk that existing authorisations become invalid or that compliance obligations become unclear. The Order addresses that risk through targeted cessation and comprehensive deeming provisions.
From a practitioner’s perspective, the most consequential features are:
- Clear effective date (1 November 2016) for cessation of the Medicines Act’s application to oral dental gums;
- Deeming of registrations for products with existing product licences;
- Deeming of licence types for importers, manufacturers, and wholesalers; and
- Immediate imposition of duties under the Health Products Act framework on deemed registrants and licence holders.
These provisions affect how counsel and compliance officers should advise clients on regulatory obligations after the transition. For example, a company that previously complied with Medicines Act requirements for an oral dental gum would need to ensure that its compliance systems, documentation, and regulatory submissions align with the Health Products Act and the Oral Dental Gums Regulations from the effective date.
Additionally, the Order’s definition of “oral dental gum” and its R&D carve-out matter for classification disputes. If a product is intended for dental health or oral hygiene and is a chewing gum-like substance, it is likely within scope. Conversely, if it is manufactured or imported solely for research and development by a properly registered person under the Control of Manufacture Act, it may fall outside the definition and therefore outside the cessation effect.
Related Legislation
- Health Products Act (Cap. 122D)
- Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016)
- Medicines Act (Cap. 176)
- Control of Manufacture Act (Cap. 57)
Source Documents
This article provides an overview of the Medicines (Cessation of Application of Act to Oral Dental Gums) Order 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.